Comparing the Cancer Vaccine OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors
Led by OSE Immunotherapeutics · Updated on 2026-10-02
363
Participants Needed
207
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the cancer vaccine OSE2101 compared to the chemotherapy drug docetaxel in patients with metastatic non-small cell lung cancer NSCLC who have developed resistance to immune checkpoint inhibitors. This phase 3, randomized, open-label study focuses on HLA-A2 positive patients with either squamous or non-squamous NSCLC who are not candidates for surgery or radiation and lack certain genetic alterations that make them eligible for targeted therapies.
Participants will be randomly assigned in a 21 ratio to receive either OSE2101 or docetaxel. OSE2101 is given as a subcutaneous injection every three weeks for six cycles, then every eight weeks for the first year, and finally every twelve weeks until the end of the second year. Docetaxel is administered as an intravenous infusion every three weeks. The study also uses companion diagnostic devices to confirm HLA-A2 status.
Throughout the study, participants will have regular visits for treatment and monitoring. Researchers will measure overall survival from randomization until death, with an average follow-up of three years. The trial aims to assess the safety and effectiveness of OSE2101 compared to docetaxel in this patient group, with ongoing monitoring until study completion in late 2028.
CONDITIONS
Brief Title
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Research Team
C
Caroline Chevalier, MSc, MPH
B
Bérangère Vasseur, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
OSE2101
Docetaxel (trial arm)
Docetaxel (current standard care)
What it is
A therapeutic peptide‑based cancer vaccine targeting multiple tumor antigens in HLA‑A2‑positive NSCLC patients
Standard chemotherapy agent used as the active comparator arm
Standard second‑line chemotherapy for NSCLC patients progressing after immunotherapy
Role in trial
Investigational vaccine being tested for efficacy and safety
Active comparator chemotherapy arm used within the trial
Standard care reference not part of randomization in the trial
Primary use
To treat metastatic NSCLC with secondary resistance to immune checkpoint inhibitors
Chemotherapy for NSCLC in patients who failed prior immunotherapy
Commonly used as second‑line chemotherapy for NSCLC after immunotherapy failure
How it is given or performed
Given as a subcutaneous peptide vaccine with multiple injections per schedule
Administered as standard intravenous chemotherapy doses per protocol
Administered intravenously according to usual second‑line chemotherapy practice
Evidence status
Phase III ATALANTE‑1 results showed improved overall survival in HLA‑A2‑positive NSCLC with secondary ICI resistance (median OS 11.1 vs 7.5 months; HR 0.59)
Established chemotherapy with modest second‑line benefit post‑immunotherapy
Recommended second‑line option with known efficacy as per guidelines
Important risks
Lower rate of high‑grade adverse events compared to chemotherapy (e.g. ~11% grade ≥3)
Higher risk of severe toxicity such as neutropenia and asthenia (up to ~35% grade ≥3)
Known toxicities include neutropenia, fatigue, and peripheral edema
Important limitations
Benefit limited to HLA‑A2‑positive patients with secondary resistance to ICI; broader effectiveness remains untested
Offers modest survival benefit and higher toxicity in heavily pretreated patients
Effectiveness is modest with significant side effects, and results may vary by patient performance status
Patient‑relevant outcome
Associated with meaningful overall survival improvement (~3.6 months) and better safety and quality of life in this patient group
Provides survival benefit but with notable toxicity burden
Established option offering modest survival extension though side effects may impact quality of life
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Male or female aged 18 years or older
Confirmed HLA-A2 phenotype by blood test
Diagnosed with metastatic squamous or non-squamous non-small cell lung cancer not eligible for surgery or radiation
No EGFR, ALK, or ROS1 gene alterations eligible for targeted therapy
Secondary resistance to immune checkpoint inhibitor therapy
You will not qualify if you...
Presence of EGFR, ALK, or ROS1 gene alterations eligible for targeted therapy
Patients eligible for definite surgery or radiation
Lack of HLA-A2 phenotype
Other exclusion criteria as per study protocol
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are assessed for eligibility, including testing for HLA-A2 phenotype and confirmation of metastatic non-small cell lung cancer status.
1 to 2 visits
Treatment
Duration - Up to 2 years
Participants receive either OSE2101 vaccine injections or docetaxel infusions according to their assigned group, with treatment continuing for up to two years depending on the regimen.
Injections every 3 weeks for 6 cycles, then every 8 weeks for up to 1 year, then every 12 weeks until end of year 2 for OSE2101; Infusions every 3 weeks for docetaxel
Follow-up
Duration - Approximately 3 years
Participants are monitored for overall survival and safety outcomes for an average of three years from randomization.
Regular follow-up visits per study schedule
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1.